{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:01:58Z","timestamp":1792414918154,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["2018-04-10"],"award-info":[{"award-number":["2018-04-10"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2013\/10\/E\/NZ5\/00778"],"award-info":[{"award-number":["2013\/10\/E\/NZ5\/00778"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2018\/31\/D\/NZ5\/01274"],"award-info":[{"award-number":["2018\/31\/D\/NZ5\/01274"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/21\/N\/NZ5\/02585"],"award-info":[{"award-number":["2016\/21\/N\/NZ5\/02585"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001870","name":"Foundation for Polish Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","award":["2018-04-10"],"award-info":[{"award-number":["2018-04-10"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","award":["6817\/IA\/SP\/2018"],"award-info":[{"award-number":["6817\/IA\/SP\/2018"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.canlet.2021.02.020","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T21:54:55Z","timestamp":1615413295000},"page":"13-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Inhibition of the \u029f-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors"],"prefix":"10.1016","volume":"507","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-102X","authenticated-orcid":false,"given":"Monika K.","family":"Prelowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Mehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0129-7542","authenticated-orcid":false,"given":"M. Talha","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-3739","authenticated-orcid":false,"given":"Hanna","family":"Kedzierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-6635","authenticated-orcid":false,"given":"Aleksandra","family":"Cwiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9761-2833","authenticated-orcid":false,"given":"Artur","family":"Kosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6886-3556","authenticated-orcid":false,"given":"Klaudia","family":"Kaminska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-3131","authenticated-orcid":false,"given":"Anna A.","family":"Marusiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2748-9523","authenticated-orcid":false,"given":"Dominika","family":"Nowis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.02.020_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canlet.2021.02.020_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.02.020_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line","author":"L\u00fc","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2021.02.020_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","author":"L\u00fc","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2021.02.020_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.02.020_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes in particular in redox and energy metabolism","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.02.020_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2014.11.002","article-title":"Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma","author":"Salem","year":"2015","journal-title":"Redox Biol"},{"key":"10.1016\/j.canlet.2021.02.020_bib8","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11960","article-title":"Noncanonical SQSTM1\/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming","author":"Riz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.02.020_bib9","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","author":"Ling","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2021.02.020_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-Negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.02.020_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-2334","article-title":"SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival","author":"Hassanein","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.02.020_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.02.020_bib13","first-page":"1","article-title":"ASCT2\/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer","author":"van Geldermalsen","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.02.020_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/msb.20134892","article-title":"Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer","volume":"10","author":"Yang","year":"2014","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.canlet.2021.02.020_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: cell biology, physiology, and clinical opportunities","author":"Hensley","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.02.020_bib16","doi-asserted-by":"crossref","DOI":"10.1139\/o79-029","article-title":"Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney","author":"Welbourne","year":"1979","journal-title":"Can. J. Biochem."},{"key":"10.1016\/j.canlet.2021.02.020_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-016-1008-z","article-title":"Non-invasive glutamine PET reflects pharmacological inhibition of BRAFV600E in vivo","author":"Schulte","year":"2017","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.canlet.2021.02.020_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/nature07823","article-title":"C-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.02.020_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2011.03.029","article-title":"Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways","author":"Watanabe","year":"2011","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.canlet.2021.02.020_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.02.020_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molonc.2015.08.003","article-title":"Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells","volume":"10","author":"Baenke","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2021.02.020_bib22","article-title":"Altered glutamine metabolism in platinum resistant ovarian cancer","author":"Hudson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.02.020_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2512","article-title":"Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors","author":"Harding","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.02.020_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4464","article-title":"Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models","author":"Schulte","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.02.020_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.02.020_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.02.020_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2021.02.020_bib28","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.02.020_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.02.020_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.02.020_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.02.020_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ccell.2015.02.006","article-title":"Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies","volume":"27","author":"Jeon","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.02.020_bib33","first-page":"E21","article-title":"Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells","volume":"112","author":"Li","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2021.02.020_bib34","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.02.020_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","author":"O'Connor","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.02.020_bib36","doi-asserted-by":"crossref","DOI":"10.1021\/jm301191p","article-title":"Design, synthesis, and pharmacological evaluation of bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors","author":"Shukla","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.02.020_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9627","article-title":"A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1\/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNS","author":"Skoulidis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.02.020_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","article-title":"SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival","volume":"19","author":"Hassanein","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.02.020_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-019-0039-6","article-title":"Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression","author":"Ni","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.canlet.2021.02.020_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2014.10.098","article-title":"2-Substituted N\u03b3-glutamylanilides as novel probes of ASCT2 with improved potency","author":"Schulte","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.canlet.2021.02.020_bib41","article-title":"MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation","author":"min Lee","year":"2017","journal-title":"Cell Metabol."}],"updated-by":[{"DOI":"10.1016\/j.canlet.2021.11.029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:52:49Z","timestamp":1778683969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"alternative-id":["S0304383521000938"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.02.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the \u029f-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}